EMEA-002155-PIP01-17
Key facts
Active substance |
Non-pathogenic bacterial lysate of Escherichia coli and Enterococcus faecalis
|
Therapeutic area |
Gastroentology-Hepatology
|
Decision number |
P/0095/2018
|
PIP number |
EMEA-002155-PIP01-17
|
Pharmaceutical form(s) |
Age-appropriate oral liquid dosage form
|
Condition(s) / indication(s) |
Treatment of irritable bowel syndrome (IBS)
|
Route(s) of administration |
Oral use
|
Contact for public enquiries |
SymbioPharm GmbH
Tel. +41 613120510
E-mail: klaus.rose@klausrose.net |
Decision type |
RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s)
|